注射用重组人Ⅱ型肿瘤坏死因子受体-抗体融合蛋白联合氨甲蝶呤治疗强直性脊柱炎患者的效果  

Effects of recombinant human type II tumor necrosis factor receptor-antibody fusion protein for injection combined with Methotrexate in treatment of patients with ankylosing spondylitis

作　　者：王彬 晋华程 房宇晨 WANG Bin;JIN Huacheng;FANG Yuchen(Department of Orthopedics of Guancheng District Hospital of Traditional Chinese Medicine,Zhengzhou 450000 Henan,China)

机构地区：[1]郑州市管城区中医院骨伤科,河南郑州450000

出　　处：《中国民康医学》2023年第5期71-73,共3页Medical Journal of Chinese People’s Health

摘　　要：目的:观察注射用重组人Ⅱ型肿瘤坏死因子受体-抗体融合蛋白联合氨甲蝶呤治疗强直性脊柱炎患者的效果。方法:选取2020年1月至2021年6月该院收治的120例强直性脊柱炎患者进行前瞻性研究,按照随机数字表法分为观察组与对照组各60例。对照组采用氨甲蝶呤治疗,观察组在对照组基础上联合注射用重组人Ⅱ型肿瘤坏死因子受体-抗体融合蛋白治疗,比较两组疗效、血清炎性因子[肿瘤坏死因子-α(TNF-α)、白细胞介素(IL)-1β及IL-17]水平、巴氏强直性脊柱炎功能活动指数(BASFI)评分、巴氏强直性脊柱炎疾病活动指数(BASDAI)评分和不良反应发生率。结果:观察组治疗总有效率为96.67%,明显高于对照组的86.67%,差异有统计学意义(P<0.05);治疗后,两组TNF-α、IL-1β、IL-17水平以及BASFI、BASDAI评分均低于治疗前,且观察组低于对照组,差异有统计学意义(P<0.05);两组不良反应发生率比较,差异无统计学意义(P>0.05)。结论:注射用重组人Ⅱ型肿瘤坏死因子受体-抗体融合蛋白联合氨甲蝶呤治疗强直性脊柱炎患者可提高治疗总有效率,降低炎性因子水平和BASFI、BASDAI评分,效果优于单纯氨甲蝶呤治疗。Objective:To observe effects of recombinant human type II tumor necrosis factor receptor-antibody fusion protein for injection combined with Methotrexate in treatment of patients with ankylosing spondylitis.Methods:A prospective study was conducted on 120 patients with ankylosing spondylitis admitted to this hospital from January 2020 to June 2021.They were divided into observation group and control group according to the random number table method,60 cases in each.The control group was treated with Methotrexate,while the observation group was treated with recombinant human type II tumor necrosis factor receptor-antibody fusion protein for injection on the basis of that of the control group.The efficacy,the serum inflammatory factor levels[tumor necrosis factor-α(TNF-α),interleukin(IL)-1βand IL-17],the Bath ankylosing spondylitis functional index(BASFI)score,the Bath ankylosing spondylitis disease activity index(BASDAI)score,and the incidence of adverse reactions were compared between the two groups.Results:The total effective rate of treatment in the observation group was 96.67%,which was significantly higher than 86.67%in the control group,and the difference was statistically significant(P<0.05).After the treatment,the levels of TNF-α,IL-1β,IL-17 and the BASFI and BASDAI scores in the two groups were lower than those before the treatment,those in the observation group were lower than the control group,and the differences were statistically significant(P<0.05).However,there was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusions:Recombinant human type II tumor necrosis factor receptor-antibody fusion protein for injection combined with Methotrexate in the treatment of the patients with ankylosing spondylitis can improve the total effective rate of treatment and reduce the levels of inflammatory factors and the BASFI and BASDAI scores.Moreover,it is superior to single Methotrexate.

关 键 词：强直性脊柱炎 注射用重组人Ⅱ型肿瘤坏死因子受体-抗体融合蛋白 炎性因子 BASFI评分 BASDAI评分 不良反应 

分 类 号：R593.23[医药卫生—内科学]